CD8A and neoplasm: Only IT mPH-762 treatment at 2 mg generated treated tumor-specifically reactive memory CD8+ T cells, as indicated by their increased IFN-γ and TNF-α production specifically in response to Hepa1-6-challenge (but not to an unrelated murine tumor, CT26 challenge); in contrast, similar reactivity was not observed for animals treated IT with PBS, NTC or with mPH-762 at 0.5 mg (Figure 5).